Boehringer Ingelheim increases access to the medication for the treatment of HIV/AIDS

Boehringer IngelheimBoehringer Ingelheim is announcing an expansion of its Intellectual Property (IP) enforcement policy. The IP enforcement policy had already been amended in 2007 by an easy-to-use, non-assert declaration for Viramune® (nevirapine). At present, twelve WHO pre-qualified manufacturers qualify for the non-assert declaration for Viramune® and Boehringer Ingelheim grants tiered pricing to 78 countries.

Under the revised IP enforcement policy, Boehringer Ingelheim will not enforce its nevirapine patent rights, provided generic versions of Viramune® are of acceptable quality and for use in eligible countries. Today's expanded IP enforcement policy will further increase access to HIV/Aids medication in emerging economies.

The decision to waive enforcement of its patent rights for nevirapine use in a total of 135 low- and middle-income countries is the result of a close cooperation between Boehringer Ingelheim and the Medicines Patent Pool (MPP). The United Nations-backed public health organisation MPP works to improve access to HIV, Hepatitis C and tuberculosis medicines in low- and middle-income countries.

"The core task of Boehringer Ingelheim is the research and development of innovative medication. We feel responsible for making innovative medicines like nevirapine accessible and affordable for patients in developing countries," explains Yew Looi Liew, Senior Vice President Emerging Markets at Boehringer Ingelheim. "Through making these medicines available we address an unmet medical need and can save lives - especially in low-income societies."

The research-driven company Boehringer Ingelheim has a significant history in the commitment of improving access to its anti-retroviral medication. The Viramune® Donation Programme was initiated in 2000 in order to facilitating access of anti-retroviral drugs for pregnant women with HIV/Aids. From its inception, the initiative reached more than two million mother-child-pairs in 164 programmes in 60 countries worldwide.

The Medicines Patent Pool (MPP) seeks to increase access to medicines by negotiating with pharmaceutical companies for voluntary licenses on their medicines patents. The work of the MPP has been endorsed by the World Health Organization, UNAIDS, The Global Fund to Fight Aids, Tuberculosis and Malaria, and the Group of Eight (G8) Industrialised Nations (France, Germany, Italy, United Kingdom, Japan, United States, Canada and Russia). The MPP was founded and continues to be funded by the innovative financing mechanism UNITAID.

About Boehringer Ingelheim
Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative "Making More Health" while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does.

In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent ofnet sales.

Most Popular Now

Novartis announces plan to initiate clinical trial…

Novartis today announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the effic...

Sanofi and Regeneron provide update on U.S. Phase …

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzar...

Gilead announces results from Phase 3 trial of inv…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigation...

AstraZeneca and Oxford University announce landmar…

AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine a...

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Loss of smell associated with milder clinical cour…

Following an earlier study that validated the loss of smell and taste as indicators of SARS-CoV-2 infection, researchers at UC San Diego Health report in newly published ...

Can an existing HIV medication slow the spread of …

A team of scientists from St. Michael's Hospital, Sinai Health and Sunnybrook Health Sciences Centre have launched a clinical trial to understand whether an existing drug...